Inovio Biomedical (INO) Delivers “Promising” Results in Animal Study for Novel H1N1 Influenza Vaccine Candidate
Inovio Biomedical is engaged in the design, development and delivery of DNA vaccines for the prevention and treatment of cancers and infectious diseases. The company today announced that a combination of its synthetic consensus (SynCon) H1N1 influenza vaccine candidates achieved protective antibody responses against A/H1N1 (2009) in 100% of the ferrets in its animal study. While the company has delivered “promising” results in similar studies with mice and pigs, according to the company, the ferret model is the most similar representation of human influenza. Today’s positive news marks a significant achievement for the company and its vaccine development. Dr. J.…